Saskia Middeldorp

ORCID: 0000-0002-1006-6420 · 7 papers in corpus
other 2024
Research and practice in thrombosis and haemostasis ·doi:10.1016/j.rpth.2024.102448
review 2024
Hematology. American Society of Hematology. Education Program ·doi:10.1182/hematology.2024000593

Hormone-related venous thromboembolism (VTE) is common and entails scenarios in which VTE occurs during exposure to exogenous or endogenous female sex hormones, typically estrogen and progestogen. For the management of hormone-related VTE, …

guideline 2023
Human reproduction open ·doi:10.1093/hropen/hoad002

STUDY QUESTION: What are the updates for the recommended management of women with recurrent pregnancy loss (RPL) based on the best available evidence in the literature from 2017 to 2022? SUMMARY ANSWER: The guideline development group (GDG…

other 2022
Thrombosis research ·doi:10.1016/j.thromres.2022.07.014
rct 2021
Research and practice in thrombosis and haemostasis ·doi:10.1002/rth2.12474

BACKGROUND: Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin. OBJECTIVES: To demonstrate and compare menstrual patterns …

observational 2020
BMJ open ·doi:10.1136/bmjopen-2020-039759

OBJECTIVE: To determine how the representation of women's health has changed in clinical studies over the course of 70 years. DESIGN: Observational study of 71 866 research articles published between 1948 and 2018 in The BMJ. MAIN OUTCOME…

observational 2016
Blood ·doi:10.1182/blood-2015-08-665927

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of the potential for fetal complications. It is unknown whether the use of hormonal therapy, especially those containing estrogens, is associated with recur…